Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record

• Published in: Genes & diseases Vol. 10; no. 3; pp. 1019 - 1028
• Main Authors: Shi, Zongqi, Zheng, Huizhi, Han, Miaomiao, Hu, Jieli, Hu, Yuan, Li, Xiaosong, Zhu, Wenyan, He, Xinjun, Deng, Haijun, Long, Quanxin, Huang, Ailong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2023; Chongqing Medical University; KeAi Communications Co., Ltd
• Subjects: anti-HBs; Chronic hepatitis B Infection; Clinical outcomes after HBsAg seroclearance; Durability of HBsAg seroclearance; Full Length; Interferon monotherapy; Nucleoside analogs monotherapy; anti-HBs; Interferon monotherapy; Nucleoside analogs monotherapy; Clinical outcomes after HBsAg seroclearance; Chronic hepatitis B Infection; Durability of HBsAg seroclearance

Little is known about the difference in durability of HBsAg seroclearance induced by nucleoside analogs (NAs) or by interferon (IFN). A real-world, retrospective cohort study was conducted. Patients were assigned into two groups: NAs monotherapy-induced HBsAg seroclearance subjects and IFN monothera...